BR112020022576A2 - uso de canaquinumabe - Google Patents
uso de canaquinumabe Download PDFInfo
- Publication number
- BR112020022576A2 BR112020022576A2 BR112020022576-2A BR112020022576A BR112020022576A2 BR 112020022576 A2 BR112020022576 A2 BR 112020022576A2 BR 112020022576 A BR112020022576 A BR 112020022576A BR 112020022576 A2 BR112020022576 A2 BR 112020022576A2
- Authority
- BR
- Brazil
- Prior art keywords
- administration
- patient
- fact
- canaquinumab
- hscrp
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 14
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 88
- 229960001838 canakinumab Drugs 0.000 claims description 32
- 239000005557 antagonist Substances 0.000 claims description 26
- 230000002411 adverse Effects 0.000 claims description 17
- 208000010125 myocardial infarction Diseases 0.000 claims description 17
- 102100032752 C-reactive protein Human genes 0.000 claims description 16
- 108090001005 Interleukin-6 Proteins 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 11
- 238000013150 knee replacement Methods 0.000 claims description 11
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 4
- 238000011541 total hip replacement Methods 0.000 claims description 4
- 239000002876 beta blocker Substances 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 24
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000000902 placebo Substances 0.000 description 41
- 229940068196 placebo Drugs 0.000 description 41
- 238000012360 testing method Methods 0.000 description 35
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 26
- 102000003810 Interleukin-18 Human genes 0.000 description 22
- 108090000171 Interleukin-18 Proteins 0.000 description 22
- 230000009467 reduction Effects 0.000 description 22
- 150000001413 amino acids Chemical group 0.000 description 19
- 239000012634 fragment Substances 0.000 description 19
- 210000003127 knee Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 239000000090 biomarker Substances 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000002526 effect on cardiovascular system Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000007211 cardiovascular event Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 206010057178 Osteoarthropathies Diseases 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011540 hip replacement Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000000250 revascularization Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 102100039065 Interleukin-1 beta Human genes 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 206010060933 Adverse event Diseases 0.000 description 3
- 206010002388 Angina unstable Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 235000009421 Myristica fragrans Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000007814 Unstable Angina Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000007214 atherothrombosis Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 239000001115 mace Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000013146 percutaneous coronary intervention Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000009863 secondary prevention Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010048998 Acute phase reaction Diseases 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 2
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 102100036788 Tubulin beta-4A chain Human genes 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004658 acute-phase response Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000004848 nephelometry Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000013689 Abnormality of movement Diseases 0.000 description 1
- 241000746129 Aniara Species 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 102100039898 Interleukin-18 Human genes 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000009430 Thespesia populnea Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 102000043959 human IL18 Human genes 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002050 international nonproprietary name Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011240 pooled analysis Methods 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000002400 pro-nociceptive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011247 total mesorectal excision Methods 0.000 description 1
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669071P | 2018-05-09 | 2018-05-09 | |
| US62/669,071 | 2018-05-09 | ||
| PCT/IB2018/056455 WO2019215484A1 (en) | 2018-05-09 | 2018-08-24 | Use of canakinumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020022576A2 true BR112020022576A2 (pt) | 2021-02-09 |
Family
ID=63638190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020022576-2A BR112020022576A2 (pt) | 2018-05-09 | 2018-08-24 | uso de canaquinumabe |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210371511A1 (enExample) |
| EP (1) | EP3790576A1 (enExample) |
| JP (2) | JP2021523894A (enExample) |
| KR (1) | KR20210008847A (enExample) |
| CN (2) | CN119746057A (enExample) |
| AU (1) | AU2018422406A1 (enExample) |
| BR (1) | BR112020022576A2 (enExample) |
| CA (1) | CA3098277A1 (enExample) |
| CL (1) | CL2020002881A1 (enExample) |
| MX (1) | MX2020011909A (enExample) |
| TW (1) | TW201946652A (enExample) |
| WO (1) | WO2019215484A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112402359A (zh) * | 2020-11-04 | 2021-02-26 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| PL2848258T3 (pl) | 2005-10-26 | 2018-06-29 | Novartis Ag | Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta |
| HRP20251174T1 (hr) * | 2010-11-05 | 2025-11-21 | Novartis Ag | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista |
| BR112014007253A2 (pt) * | 2011-09-30 | 2017-03-28 | Novartis Ag | uso de anticorpos que se ligam a il-1beta |
| US20150203592A1 (en) * | 2013-12-02 | 2015-07-23 | Abbvie Inc. | Compositions and methods for treating osteoarthritis |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| UY37758A (es) * | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| AU2018287519B2 (en) * | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| CN107723310B (zh) * | 2017-10-19 | 2024-01-09 | 北京睿诚海汇健康科技有限公司 | 植物作为宿主在表达卡那抗体中的应用 |
-
2018
- 2018-08-24 CN CN202411634666.2A patent/CN119746057A/zh active Pending
- 2018-08-24 BR BR112020022576-2A patent/BR112020022576A2/pt not_active IP Right Cessation
- 2018-08-24 CA CA3098277A patent/CA3098277A1/en not_active Abandoned
- 2018-08-24 US US17/053,602 patent/US20210371511A1/en active Pending
- 2018-08-24 AU AU2018422406A patent/AU2018422406A1/en not_active Abandoned
- 2018-08-24 EP EP18772905.8A patent/EP3790576A1/en active Pending
- 2018-08-24 TW TW107129705A patent/TW201946652A/zh unknown
- 2018-08-24 WO PCT/IB2018/056455 patent/WO2019215484A1/en not_active Ceased
- 2018-08-24 MX MX2020011909A patent/MX2020011909A/es unknown
- 2018-08-24 JP JP2020562124A patent/JP2021523894A/ja not_active Withdrawn
- 2018-08-24 KR KR1020207035003A patent/KR20210008847A/ko not_active Withdrawn
- 2018-08-24 CN CN201880094285.6A patent/CN112584857A/zh active Pending
-
2020
- 2020-11-06 CL CL2020002881A patent/CL2020002881A1/es unknown
-
2023
- 2023-03-07 JP JP2023034283A patent/JP7713983B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020011909A (es) | 2021-01-29 |
| TW201946652A (zh) | 2019-12-16 |
| KR20210008847A (ko) | 2021-01-25 |
| AU2018422406A1 (en) | 2020-11-12 |
| CL2020002881A1 (es) | 2021-05-14 |
| JP2023071904A (ja) | 2023-05-23 |
| CA3098277A1 (en) | 2019-11-14 |
| WO2019215484A1 (en) | 2019-11-14 |
| EP3790576A1 (en) | 2021-03-17 |
| US20210371511A1 (en) | 2021-12-02 |
| JP2021523894A (ja) | 2021-09-09 |
| JP7713983B2 (ja) | 2025-07-28 |
| CN119746057A (zh) | 2025-04-04 |
| CN112584857A (zh) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghouri et al. | Update on novel pharmacological therapies for osteoarthritis | |
| US20210371512A1 (en) | Use of IL-1 beta Binding Antibodies | |
| US20090022717A1 (en) | Antibodies that bind cxcr7 epitopes | |
| BR112021010789A2 (pt) | Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar | |
| JP2021503476A (ja) | Ｉｌ−１７アンタゴニストを用いて化膿性汗腺炎を治療すること | |
| Gow et al. | Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects | |
| Khatri et al. | Pharmacokinetics of ABT-122, a TNF-α-and IL-17A-targeted dual-variable domain immunoglobulin, in healthy subjects and patients with rheumatoid arthritis: results from three phase I trials | |
| Wilkinson et al. | Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease | |
| US20230331834A1 (en) | Method of treating tendinopathy using interleukin-17 (il-17) | |
| JP7713983B2 (ja) | カナキヌマブの使用 | |
| JP4963701B2 (ja) | Ｃｃｘ−ｃｋｒ２を結合する試薬 | |
| KR20210142088A (ko) | 치료방법 | |
| JP2025516723A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法 | |
| TW202434624A (zh) | 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法 | |
| WO2025225719A1 (en) | Treatment and prevention of muscular dystrophy and its related diseases or disorders with satralizumab | |
| US9198903B2 (en) | Method of treating or preventing thrombosis in a patient with 5-HT2A receptor antagonist thromboserin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2672 DE 22-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |